Compare Moderna, Inc. (MRNA) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Tidewater Inc — how do they compare? Moderna, Inc. trades at $136.84 (market cap $54.14B), while Tidewater Inc trades at $92.78 (market cap $4.63B). The key difference: Moderna, Inc. is far larger — about 11.7× Tidewater Inc's market cap, and Tidewater Inc is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| MRNA | TDW | |
|---|---|---|
Market Cap | $54.14B | $4.63B |
Sector | Health | Utilities |
52-Week High | $174.38 | $100.61 |
52-Week Low | $22.36 | $47.29 |
Enterprise Value | $50.29B | $4.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
TDW trades at $92.00, down 2.4% on the day, with a bullish technical signal and support near $91. The company reported a net income of $334.66M in 2025, though 2026 earnings have missed expectations in two of the last three quarters. Recent news includes the completion of the Wilson Sons Ultratug acquisition (Business Wire, 2026-08-31), potentially expanding its offshore service capabilities.
The stock offers a 14.7% upside to the consensus price target of $105.50, supported by strong institutional interest, but faces risks from volatile earnings and competitive pressures in the energy sector. Profit margins are expected to compress in 2026, requiring careful monitoring of operational execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
